Clinical Trials Arena on MSN
Serina concludes sentinel dosing in Phase Ib trial’s cohort 1
The SER-252-1b study includes single-ascending-dose and multiple-ascending-dose components.
HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug ...
Data Safety Monitoring Committee completed initial review of sentinel dosing observations and recommended continued dosing in Cohort 1 -Dosing of ...
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a ...
Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, ...
HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled ...
HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug ...
Serina Therapeutics, Inc. announced key developments in its recent press release, highlighting plans for the first patient dosing of SER-252 in a Phase 1b clinical trial for advanced Parkinson's ...
HUNTSVILLE, Ala. & ALAMEDA, Calif.--(BUSINESS WIRE)--Serina Therapeutics, Inc. (“Serina”), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment ...
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluates subcutaneous SER-252 versus placebo Serina Therapeutics has completed sentinel dosing in Cohort 1 of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results